RxDoctor Payments Data

Christopher Bui, MD

Gastroenterology · Santa Ana, CANPI 1811061468

Payments from drug & device makers

$145,415in general payments, 2019–2025

Across 1,069 payments — averaging $136.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59K
  • Gilead$59K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$13K
  • Nestle Healthcare Nutrition Inc.$2K
  • Lilly USA, LLC$2K
  • Aimmune Therapeutics, Inc.$1K
  • plus $9K from 37 others

What the payments were for

  • Consulting fees$2,3162%
  • Speaking & faculty fees$113,15078%
  • Travel & lodging$2,9702%
  • Food & beverage$26,88418%
  • Education$150%
  • Gifts$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,415 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$284,005
Medicare patients
973
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase1,112$1,523,387
ZenpepLipase/Protease/Amylase820$1,413,957
VemlidyTenofovir Alafenamide841$1,221,004
LinzessLinaclotide873$523,813
XifaxanRifaximin137$429,255
Dexlansoprazole DrDexlansoprazole1,096$217,266
VoqueznaVonoprazan Fumarate212$137,455
Entecavir584$118,146
TrulancePlecanatide162$99,716
RezdiffraResmetirom23$91,345
IbsrelaTenapanor Hcl44$76,724
VascepaIcosapent Ethyl91$40,193
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates273$16,812
VireadTenofovir Disoproxil Fumarate12$14,798
Famotidine2,371$11,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$59,122$2,047,2001,985 claims
Aimmune Therapeutics, Inc.Zenpep$1,436$1,413,957820 claims
GileadVemlidy, Viread$58,755$1,235,802853 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$13,349$528,970299 claims
Phathom Pharmaceuticals, Inc.Voquezna$403$137,455212 claims
Madrigal PharmaceuticalsRezdiffra$442$91,34523 claims
Ardelyx, Inc.Ibsrela$861$76,72444 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant, Motegrity$203$15,48939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →